Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc)-associated, interstitial lung disease (ILD).
aTyr Pharma Receives FDA Fast Track Designation For Efzofitimod For Treatment Of Systemic Sclerosis-Associated Interstitial Lung Disease
aTyr Pharma, Inc. (NASDAQ:LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S.
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Piper Sandler Maintains Overweight on aTyr Pharma, Raises Price Target to $14
Piper Sandler analyst Edward Tenthoff maintains aTyr Pharma (NASDAQ:LIFE) with a Overweight and raises the price target from $11 to $14.
aTyr Pharma: Q2 Earnings Insights
aTyr Pharma (NASDAQ:LIFE) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell
• Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
A Preview Of aTyr Pharma’s Earnings
aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Monday, 2022-08-15. Here's what investors need to know before the announcement.
Analysts estimate that aTyr Pharma will report an earnings per share (EPS) of $-0.38.